7 results
In this study, we want to find out whether the new drug capmatinib is more effective (i.e. better inhibits the growth of cancer cells) than the widely used chemotherapy docetaxel. In addition, it will be assessed whether treatment with capmatinib is…
The study will look at patients with Squamous Cell Head and Neck Cancer (SCCHN) whose tumours express a certain type of protein called PD-L1. The research aims to compare a new drug called nivolumab against Investigator's choice of chemotherapy…
Improvement in OS is generally accepted as the best measure of clinical benefit forpatients with advanced/unresectable or metastatic NSCLC. The assumption thattreatment with MPDL3280A will prolong OS compared with treatment with docetaxel isbased on…
The primary objective of this study is to compare the overall survival (OS) of ramucirumab DP administered in combination with docetaxel versus docetaxel with placebo as therapy for patients with Stage IV non-small cell lung cancer (NSCLC) who have…
This is a phase III, open-label, multicenter, randomized study to investigate the efficacy and safety of atezolizumab (anti PDL1 antibody) compared with chemotherapy in patients with locally advanced or metastatic urothelial bladder cancer after…
To investigate the feasibility of the implementation of a point-of-care immunological test based on blood cells of all trauma patients with the aid of an automated load-and-go flow cytometer in an acute trauma care setting at the shock room.
Primary objective: To evaluate the efficacy of MPDL3280A in patients with locally advanced or metastatic solid tumor whom, in the opinion of the investigator, based on available clinical data, may benefit from treatment with anti PD-L1 immunotherapy…